The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

References

• World Health Organization. Coronavirus disease (COVID-19) pandemic. on 2021 Jul 3. Accessed at https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Rizzo M, Foresti L, Montano N. Comparison of reported deaths from COVID-19 and increase in total mortality in Italy. JAMA Intern Med. 2020;180:1250–1252.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. COVID-19 Lombardy ICU network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–1581.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Stoian AP, Banerjee Y, Rizvi AA, et al. Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management. Metab Syndr Relat Disord. 2020;18:173–175.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Bhana S, Czupryniak L, et al. Management of patients with diabetes and obesity in the COVID-19 era: experiences and learnings from South and East Europe, the Middle East, and Africa. Diabetes Res Clin Pract. 2021;172:108617.
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736–E741.
   PubMed Web of Science ®Google Scholar
• Longo M, Caruso P, Maiorino MI, et al. Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovasc Diabetol. 2020;19(1):115.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Standl E, Catrinoiu D, et al. Diabetes : issues for the management of people with diabetes and COVID-19 in ICU. Cardiovasc Diabetol. 2020;19(1):114.
   PubMed Web of Science ®Google Scholar
• Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044.
   PubMed Web of Science ®Google Scholar
• Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32(3):437–446 e435.
   PubMed Web of Science ®Google Scholar
• Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: what should be considered? Diabetes Res Clin Pract. 2020;163:108151.
   PubMed Web of Science ®Google Scholar
• Shaw K. The impact of diabetes on COVID-19 infection. Pract Diab. 2020;37:79–81.
   Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382:1708–1720.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547.
   PubMed Web of Science ®Google Scholar
• Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(1068–1077.e3):1068–1077.e3.
   Google Scholar
• Fadini GP, Morieri ML, Longato E, et al. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43:867–869.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Castagna A, Rovere-Querini P, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020;217:108509.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705–1714.
   PubMed Web of Science ®Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
   PubMed Web of Science ®Google Scholar
• Rizvi AA, Janez A, Al Mahmeed W, et al. Diabetes and COVID-19: a tale of two pandemics. J Cardiovasc Pharmacol. 2021 Jun 25;78(1):e1–e2. Online ahead of print.
   PubMedGoogle Scholar
• Pantea Stoian A, Pricop-Jeckstadt M, Pana A, et al. Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. Sci Rep. 2020;10:21613.
   PubMed Web of Science ®Google Scholar
• Pugliese G, Vitale M, Resi V, et al. Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? Acta Diabetol. 2020;57:1275–1285.
   PubMed Web of Science ®Google Scholar
• Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823–833.
   PubMed Web of Science ®Google Scholar
• Coppelli A, Giannarelli R, Aragona M, et al. Pisa COVID-19 study group. hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care. 2020;43:2345–2348.
   PubMed Web of Science ®Google Scholar
• Banach M, Gaita D, Haluzik M; Cardio-Metabolic Academy Europe East. Adoption of the ADA/EASD guidelines in. 10 Eastern and Southern European countries: physician survey and good clinical practice recommendations from an international expert panel. Diabetes Res Clin Pract. 2021;172:108535.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin Investig Drugs. 2009;18:1495–1503.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102.
   PubMed Web of Science ®Google Scholar
• Sachinidis A, Nikolic D, Stoian AP, et al. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020;111:154343.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B, et al. T-emerge 2 study group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498–504.
   PubMed Web of Science ®Google Scholar
• Xue X, Ren Z, Zhang A, et al. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Int J Clin Pract. 2016;70:649–656.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2814–2821.
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Maleki M, Sathyapalan T, et al. Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sci. 2020;241:117152.
   PubMed Web of Science ®Google Scholar
• Maranta F, Cianfanelli L, Rizzo M, et al. Filling the gap between guidelines and real world in the cardiovascular approach to the diabetic patients: the need for a call to action. Int J Cardiol. 2021;329:205–207.
   PubMed Web of Science ®Google Scholar
• Stoian AP, Papanas N, Prazny M, et al. Incretin-Based Therapies Role in COVID-19 Era: evolving Insights. J Cardiovasc Pharmacol Ther. 2020 Jul 3;25(6):494–496. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Kahkoska AR, Abrahamsen TJ, Alexander GC, et al. N3C consortium. association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 Outcomes. Diabetes Care. 2021 Jun 16:dc210065.
   PubMed Web of Science ®Google Scholar
• Israelsen SB, Pottegård A, Sandholdt H, et al. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes Metab. 2021;23:1397–1401.
   PubMed Web of Science ®Google Scholar
• Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9:293–303.
   PubMed Web of Science ®Google Scholar
• Nyland JE, Raja-Khan NT, Bettermann K, et al. Diabetes, drug treatment and mortality in COVID-19: a multinational retrospective cohort study. SSRN Electron J. 2020. DOI:https://doi.org/10.2139/ssrn.3725612.
   Google Scholar
• Nauck MA, Meier JJ, Cavender MA. Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–870.
   PubMed Web of Science ®Google Scholar
• Verges B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37(6):477–488.
   PubMed Web of Science ®Google Scholar
• Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and ##on. Front Endocrinol (Lausanne). 2018;9:672.
   PubMed Web of Science ®Google Scholar
• Li Z, Li S, Wang N, et al. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-kappaB and MAPK pathways via GLP-1R. Biomed Pharmacother. 2020;130:110523.
   PubMed Web of Science ®Google Scholar
• Steven S, Hausding M, Kroller-Schon S, et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol. 2015;110(2):6.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang X, Wang Y, et al. NLRP3 inflammasome activation regulated by NF-kappaB and DAPK contributed to paraquat-induced acute kidney injury. Immunol Res. 2017;65(3):687–698.
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, et al. NF-kappaB signaling in inflammation. Signal Transduct Target Ther. 2017;2.
   Web of Science ®Google Scholar
• Song P, Li W, Xie J, et al. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280–287.
   PubMed Web of Science ®Google Scholar
• Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401–409.
   PubMed Web of Science ®Google Scholar
• Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 2019;10(11):822.
   PubMedGoogle Scholar
• Wang J, Saguner AM, An J, et al. Dysfunctional coagulation in COVID-19: from Cell to Bedside. Adv Ther. 2020;37(7):3033–3039.
   PubMed Web of Science ®Google Scholar
• Sternkopf M, Nagy M, Baaten C, et al. Native, intact glucagon-like peptide 1 Is a natural suppressor of thrombus growth under physiological flow conditions. Arterioscler Thromb Vasc Biol. 2020;40(3):e65–e77.
   PubMed Web of Science ®Google Scholar
• Carlessi R, Chen Y, Rowlands J, et al. GLP-1 receptor signalling promotes beta-cell glucose metabolism via mTOR-dependent HIF-1alpha activation. Sci Rep. 2017;7(1):2661.
   PubMedGoogle Scholar
• Majumdar G, Wright J, Markowitz P, et al. Insulin stimulates and diabetes inhibits O-linked N-acetylglucosamine transferase and O-glycosylation of Sp1. Diabetes. 2004;53(12):3184–3192.
   PubMed Web of Science ®Google Scholar
• Zhao P, Praissman JL, Grant OC, et al. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. 2020.
   Google Scholar
• de Queiroz RM, Oliveira IA, Piva B, et al. Dias WB: hexosamine Biosynthetic Pathway and Glycosylation Regulate Cell Migration in Melanoma Cells. Front Oncol. 2019;9:116.
   PubMed Web of Science ®Google Scholar
• Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019;17(1):52.
   PubMed Web of Science ®Google Scholar
• Ma J, Hart GW. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev Proteomics. 2013;10(4):365–380.
   PubMed Web of Science ®Google Scholar
• Sun YH, He L, Yan MY, et al. Overexpression of GLP-1 receptors suppresses proliferation and cytokine release by airway smooth muscle cells of patients with chronic obstructive pulmonary disease via activation of ABCA1. Mol Med Rep. 2017;16(1):929–936.
   PubMed Web of Science ®Google Scholar
• Huang J, Yi H, Zhao C, et al. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:3191–3202.
   PubMed Web of Science ®Google Scholar
• Pal R, Bhansali A:COVID-19. diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract. 2020;162:108132.
   PubMed Web of Science ®Google Scholar
• Monda VM, Porcellati F, Strollo F, et al. ACE2 and SARS-CoV-2 infection: might GLP-1 receptor agonists play a role? Diabetes Ther. 2020;11(9):1909–1914.
   PubMed Web of Science ®Google Scholar
• Florindo HF, Kleiner R, Vaskovich-Koubi D, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020;15(8):630–645.
   PubMed Web of Science ®Google Scholar
• Gracia-Ramos AE. Is the ACE2 overexpression a risk factor for COVID-19 infection? Arch Med Res. 2020;51(4):345–346.
   PubMed Web of Science ®Google Scholar
• Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648–654.
   PubMed Web of Science ®Google Scholar
• Stoian AP, Catrinoiu D, Rizzo M, et al., COVID-19 and diabetes. Why it is a different story. Diabetes Metab Res Rev. 2020 Jun 27:e3379. Online ahead of print. DOI:https://doi.org/10.1002/dmrr.3379.
   Google Scholar
• Stoian AP, Toth PP, Kempler P, et al., Gender differences in the battle against COVID-19: impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. Int J Clin Pract. 2020 Aug 8:e13666. Online ahead of print. DOI:https://doi.org/10.1111/ijcp.13666.
   Google Scholar
• Babapoor-Farrokhran S, Gill D, Walker J, et al. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020 Jul 15;253:117723.
   PubMed Web of Science ®Google Scholar